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Abstract
Background: Although several studies have been conducted on the role of surgery in localized neuroblastoma, the
impact of surgical timing and extent of primary tumor resection on outcome in high-risk patients remains controversial.
Methods: Patients from the German neuroblastoma trial NB97 with localized neuroblastoma INSS stage 1–3
age > 18 months were included for retrospective analysis. Imaging reports were reviewed by two independent
physicians for Image Defined Risk Factors (IDRF). Operation notes and corresponding imaging reports were analyzed
for surgical radicality. The extent of tumor resection was classified as complete resection (95–100%), gross total
resection (90–95%), incomplete resection (50–90%), and biopsy (<50%) and correlated with local control rate and
outcome. Patients were stratified according to the International Neuroblastoma Risk Group (INRG) staging system.
Survival curves were estimated according to the method of Kaplan and Meier and compared by the log-rank test.
Results: A total of 179 patients were included in this study. 77 patients underwent more than one primary
tumor operation. After best surgery, 68.7% of patients achieved complete resection of the primary tumor, 16.
8% gross total resection, 14.0% incomplete surgery, and 0.5% biopsy only. The cumulative complication rate
was 20.3% and the surgery associated mortality rate was 1.1%. Image defined risk factors (IDRF) predicted the
extent of resection. Patients with complete resection had a better local-progression-free survival (LPFS), event-
free survival (EFS) and OS (overall survival) than the other groups. Subgroup analyses showed better EFS, LPFS
and OS for patients with complete resection in INRG high-risk patients. Multivariable analyses revealed resection
(complete vs. other), and MYCN (non-amplified vs. amplified) as independent prognostic factors for EFS, LPFS and OS.
Conclusions: In patients with localized neuroblastoma age 18 months or older, especially in INRG high-risk patients
harboring MYCN amplification, extended surgery of the primary tumor site improved local control rate and survival
with an acceptable risk of complications.
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Background
Neuroblastoma is the most common solid extracranial
malignancy of childhood and the most common ma-
lignant tumor in infants [1]. Despite the advances in
multidrug therapy, surgery still plays a major role in
treatment of neuroblastoma (NB) [2]. Children pre-
senting with localized disease have an overall better
prognosis, mainly depending on the degree of tumor
resection [3]. Indeed, completely resected tumors
(INSS stage 1) rarely relapse and do not require post-
operative chemotherapy [4, 5]. There is, however, still
a controversy regarding the value of radical surgery
for extended local disease [2]. Biological and clinical
prognostic markers may help to stratify risks and
guide therapy in these patients, but prospective
randomized trials with surgical endpoints are still
missing. In 2008, the INRG group implemented a
pretreatment risk stratification considering age,
MYCN amplification, histological tumor grade, Image
Defined Risk Factors and 11q deletion to classify NB
patients into very low-, low-, intermediate- and high-
risk patients [6]. In this study, we analyzed the impact
of the extent of tumor resection on outcome of
patients older than 18 months with localized non-
metastatic NB aged, who were treated according to
the German prospective clinical trial NB97.
Methods
All patients registered by the German prospective clinical
trial NB97 between November 1, 1996, and September 30,
2004, were included in this analysis when they met the fol-
lowing criteria: stage 1–3 neuroblastoma diagnosed ac-
cording to the International Neuroblastoma Staging
System criteria [7]; age at diagnosis >18 months but less
than 21 years. Written informed consent was obtained
from patients or their guardians for participation in the
study design, data collection and treatment (Registration
number: NCT00017225, ClinicalTrials.gov).
The NB97 trial was a randomized trial comparing
ASCT (autologous stem cell transplantation) and oral
maintenance chemotherapy in high-risk patients.
According to the NB97 protocol, the patients with
localized NB were prospectively stratified in NB97
high-risk, NB97 standard-risk or NB97 low-risk sub-
groups according to INSS stage, age, MYCN-Status
and threatening symptoms. NB97 standard-risk pa-
tients received 4 cycles of chemotherapy after first
surgery and a second resection when necessary
whereas NB97 low-risk patients were observed for up
to 12 months with examinations and staging every
6 weeks. NB97 high-risk patients were randomized
and received ASCT or oral maintenance therapy. The
trial protocol had been evaluated by the Institutional
Ethical Boards of the University of Cologne and
participating hospitals. All patients participated in the
trial after informed consent and on voluntary basis.
Trial protocol and results of the primary trial end
point have been published before [8, 9]. The NB97
protocol also provided clear recommendations on
timing and extent of tumor resection. For example,
initial or delayed complete resection was advised
when no vascular structures or adjacent organs were
involved. Incomplete resection was acceptable to re-
duce the risk of acute complications and long-term
organ impairments. Nephrectomy or insertion of vas-
cular prostheses was discouraged. Therefore, complete
initial resection was reserved only for patients with
well-encapsulated primary tumors. All other patients
were recommended to undergo second look operations
after four to six cycles of induction chemotherapy. More-
over, radiation therapy of 40 Gy was advised for patients
with unresectable residuals of the primary tumor present
after induction chemotherapy. Finally, radiation doses less
than 40 Gy were applied to protect adjacent structures
with low radiation tolerance [10]. Data on extent and
complications of resection were collected prospectively
using case report forms.
For this analysis, imaging reports, operation notes and
pathology reports were retrospectively reviewed by two
independent experienced physicians, and discrepant re-
sults were clarified after repeated joint review of the pa-
tients’ files. In this study, we distinguished between two
types of operations, as described before [11]. Briefly, first
operation was the tumor operation performed before or
within the first six cycles of induction chemotherapy,
and best operation was the most extensive removal of
primary tumor tissue done at any time during first-line
therapy. For outcome analysis, the extent of resection
was classified as follows: no operation or biopsy remov-
ing less than 50% of tumor tissue; incomplete resection
of 50% to less than 90% of tumor volume present at the
time of surgery; gross total resection removing more
than 90% of the tumor; or complete resection without
macroscopic postoperative tumor residuals. It was not
possible to include the category of microscopic complete
resection because neuroblastomas were rarely removed
in toto, and therefore, the pathologist often received
several tumor fragments, making confirmation of micro-
scopic complete resection impossible. IDRF were not
established in 1997, and therefore, they had to be assessed
retrospectively by review of initial imaging and operation
notes based on the definitions published by the European
International Society of Pediatric Oncology Neuroblast-
oma Group [12] and the International Neuroblastoma
Risk Group [13, 14]. During induction chemotherapy, re-
staging, including magnetic resonance imaging of the
primary tumor site, bone marrow assessment, and metaio-
dobenzylguanidine (MIBG) scintigraphy, was scheduled
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after four to six chemotherapy cycles. If progression or re-
lapse was suspected, complete staging was necessary. Dis-
ease status and response to treatment were categorized as
complete remission, very good partial remission, partial
remission, stable disease, or progression according to the
published International Neuroblastoma Response Criteria
[7]. Pretreatment Risk Stratification was performed retro-
spectively according to INRG staging system [6] consider-
ing age, MYCN amplification, histological grade, IDRF
and 11q deletion stratifying all patients into INRG very
low-, INRG low-, INRG intermediate- and INRG high-
risk. Histology was defined by INPC guidelines as de-
scribed before [15].
Statistical analysis
For statistical analysis, the IBM SPSS software (Version
24.0.0; Armonk, NY, IBM Corp.) and R version 3.3.1
were used. Proportions were compared by Fisher’s exact
test. Survival curves were estimated according to the
method of Kaplan and Meier and compared by the log-
rank test. Event-free survival (EFS) time was calculated
as the time from diagnosis to event or last examination
if the patient had no event. Relapse, progression, and
death from disease or surgery-related were regarded as
events. Local progression–free survival (LPFS) was cal-
culated from diagnosis to relapse or progression of the
primary tumor site or last examination if the patient had
no local recurrence. This means that patients who died
from metastatic disease without progression at the pri-
mary tumor site were censored at the time of death for
LPFS analysis. Overall survival (OS) was calculated as
the time from diagnosis to death from disease or
surgery-related or last examination if the patient sur-
vived. Multivariable backward selected Cox regression
analyses were performed to analyze the prognostic value
of the following factors: stage (1 or 2 vs. 3), extent of
best resection (complete vs. other), MYCN status (ampli-
fied vs. not amplified) and IDRF (no vs. >1). The likeli-
hood ratio test p-value for inclusion was p ≤ 0.05.
Results
Patients
Among 1121 patients in the NB97 trial, 191 patients
with INSS stage 1–3 >18 months were eligible for
analysis. Patients with INSS stage 4 disease (n = 383)
and patients with non-stage 4 neuroblastoma <18 months
of age (n = 547) did not meet inclusion criteria. Two pa-
tients with ganglioneuroma and 10 patients with an early
progression within the first 40 days of chemotherapy were
excluded from the study. 179 patients with localized
neuroblastoma met all inclusion criteria (Fig. 1). The me-
dian age at diagnosis was 3.64 years (range, 1.5 to
Fig. 1 Patient flow diagram
Fischer et al. BMC Cancer  (2017) 17:520 Page 3 of 8
20.8 years), and the median observation time of the
surviving patients was 10.2 years (range, 0.5 to
17.3 years). 105 events were recorded. Among 30
relapses, there were 9 local relapses and in 35 pa-
tients with progression, we found 27 localized
progressions of the primary tumor site. Thirty-three
patients died. Table 1 lists details of the patients’ key
characteristics.
Before or during induction chemotherapy, complete
resection was achieved in 83 patients (46.4%), gross
total resection in 14 patients (7.8%), incomplete resec-
tion in 13 patients (7.3%), and biopsy in 69 patients
(38.5%). For 8 patients no imaging reports were avail-
able and extent of resection was based on the case
report forms of the trial only. During treatment, 77
patients had at least one more surgical resection of
primary tumor site. After best surgery, 68.7% of pa-
tients achieved complete resection of the primary
tumor, 16.8% gross total resection, 14.0% incomplete
surgery, and 0.5% biopsy only.
The most radical resection of the primary tumor
was achieved during first operation in 106 patients
(59.2%) and during delayed surgery in 73 patients
(40.8%). According to the protocol guidelines, 3.9%
of all patients underwent external-beam radiation
therapy of unresectable residuals of the primary
tumor, in which case a median dose of 36 Gy was
applied.
Complications during first and best operation
A total of 56 patients experienced complications dur-
ing 276 surgical interventions (20.3%) when under-
going first-line treatment for neuroblastoma. During
first operation (n = 179) horner’s syndrome (3.9%),
organ injury (3.4%) and intraoperative bleeding (2.8%)
were the most frequent complications. No surgical re-
lated deaths occurred and the total complication rate
was 19.6%. All other complications (infection, ileus,
vessel or nerve injury) occurred in <1.7% of patients,
respectively.
At best operation (n = 179) 50 complications in 40
patients occurred including horner’s syndrome with
5.6%, while organ injury and major bleeding/vessel
injury account up to 4.4% and 3.9%, respectively.
Two patients died due to surgery (1.1%). The com-
plication rate at best surgery was 27.9%. Twenty-one
patients (52.5%) out of 40 patients who experienced
one or more complications had more than one
operation.
The complication rate was not significantly different
between patients with complete resection after best sur-
gery (22.4%), patients with gross total resection (13.3%)
and incomplete resection (32%; p = 0.395).
Outcome after first operation
Complete resection could be achieved in 83/179 pa-
tients (46.4%). The 5-year EFS rate of all patients with
complete resection was 87.8% ± 3.6%, the 5-year
LPFS rate was 93.6% ± 2.7%, and the 5-year OS rate
was 92.3% ± 3.0%. For patients with gross total resec-
tion, 5-year EFS and LPFS rate were 78.6% ± 11.0%,
and the 5-year OS rate was 92.9% ± 6.9%. After in-
complete resection, 5-year EFS and LPFS rate were
66.7% ± 13.6%, and the 5-year OS rate was
83.3% ± 10.8%. Patients with biopsy only had a 5-year
EFS rate of 61.5% ± 5.9%, a 5-year LPFS rate of
66.7% ± 6.0%, and a 5-year OS rate of 75.8% ± 5.3%
after first operation. The extent of first operation had
an impact on EFS (p = 0.000), LPFS (p = 0.000), and
OS (p = 0.018; Fig. 2; Table 2). Of note, any surgical
resection compared to biopsy improved patient’s out-
come in EFS and LPFS (p = 0.001) and OS
(p = 0.002).
Outcome after best operation
Complete resection could be achieved in 123/179
patients (68.7%). The extent of resection at the best
operation was associated with better EFS (p = 0.001),
better LPFS (p = 0.001), and better OS (p = 0.020).
The 5-year EFS rate of patients with complete resec-
tion was 82.8.0% ± 3.4%, the 5-year LPFS rate was
87.1% ± 3.1%, and the 5-year OS rate was
90.8% ± 2.7%. For patients with gross total resection,
5-year EFS rate was 59.8% ± 9.0%, 5-year LPFS rate
was 62.7% ± 9.0%, and the 5-year OS rate was
75.4% ± 8.1%. After incomplete resection, 5-year EFS
rate was 58.0% ± 10.2%, 5-year LPFS rate was
66.2% ± 10.5%, and the 5-year OS rate was
70.5% ± 9.4%. One patient had a biopsy only and did
not undergo a second operation, because he died
eight months after diagnosis while undergoing ASCT.
The 5-year survival rates are listed in Table 2, and
life-tables are shown in Fig. 3. Multivariable analysis
revealed resection (complete vs. other), and MYCN
(non-amplified vs. amplified) as independent prognos-
tic factors for EFS and OS.
INSS stage and MYCN amplification
Subgroup analysis according to INSS stage after best
operation confirmed all patients with stage 1 disease
underwent complete surgical resection. In patients
with INSS stage 2, there was no significant difference
between incomplete resection, gross total resection
and complete resection in EFS (p = 0.901), LPFS
(p = 0.520) and OS (p = 0.446). But patients with
INSS stage 3 disease showed a statistical significance
according to the extent of resection in EFS
(p = 0.032) and LPFS (p = 0.034), but not in OS
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(p = 0.053). Analyzing stage 3 patients with MYCN
amplification (n = 29) and without MYCN amplifica-
tion (n = 35) separately, MYCN-amplified patients
showed a better outcome correlated to the extent of
resection at best operation (EFS p = 0.001; LPFS
p = 0.001; OS p = 0.002) whereas non-MYCN-ampli-
fied patients did not (EFS p = 0.411; LPFS p = 0.177;
OS p = 0.905).
INRG
According to INRG pretreatment risk classification 151
patients could be analyzed retrospectively. All patients
with MYCN amplification belong to the high-risk group,
resulting in 36 patients (20.1%). Patients with a histo-
logical category of GNB intermixed without MYCN
amplification or IDRF (L1) are categorized as very low-
risk (n = 88, 49.2%). Any patients with NB or nodular
GNB harboring more than one IDRF (L2) may belong to
low- (n = 4, 2.2%) or intermediate- risk (n = 23, 12.8%)
depending on grade of tumor differentiation and 11 q
aberration.
High-risk patients (n = 36) show a better EFS
(p = 0.001), LPFS (p = 0.001) and OS (p = 0.001)
after best surgery when tumor resection was complete
(Fig. 4). Patients belonging to intermediate-risk did
not benefit from complete surgery (EFS p = 0.411;
LPFS p = 0.177; OS p = 0.905).
Discussion
In our cohort, extended surgery of the primary tumor
site improved local control rate and outcome in patients
older than 18 months with localized neuroblastoma.
After complete resection during treatment the patients
had a better local-progression-free survival (LPFS),
Table 1 Key demographic and clinical characteristics of 179
patients with localized NB >18 months
Characteristic No. %
Sex
male 86 48.0
female 93 52.0
Primary tumor site
Neck 4 2.2
Chest 38 21.2
Abdomen 47 26.3
Adrenal 80 44.7
Pelvis 7 3.9
combined 3 1.7
MYCN status
non-amplified 140 78.2
amplified 36 20.1
not available 3 1.7
INSS stage
stage 1 68 38.0
stage 2 46 25.7
stage 3 65 36.3
NB97 risk group
low 96 53.6
standard 36 20.1
high 47 26.1
IDRF
yes 70 39.1
no 73 40.8
not available 36 20.1
INRG risk group
very low 88 49.2
low 4 2.2
intermediate 23 12.8
high 36 20.1
not available 28 15.6
First operation
biopsy only 69 38.5
incomplete resection 13 7.3
gross total resection 14 7.8
complete resection 83 46.4
Last operation
biopsy only 0 0
incomplete resection 17 9.5
gross total resection 20 11.2
complete resection 40 22.3
Table 1 Key demographic and clinical characteristics of 179
patients with localized NB >18 months (Continued)
Best operation
biopsy only 1 0.6
incomplete resection 25 14.0
gross total resection 30 16.8
complete resection 123 68.7
Chemotherapy
yes 82 45.8
no 97 54.2
RT of primary tumor site
yes 7 3.9
no 172 96.1
myeloablative Chemo with ASCT
yes 23 12.8
no 156 87.2
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event-free survival (EFS) and OS than the other groups.
The wide range of clinical manifestations of neuro-
blastomas, their localization and their resectability
leads to a high heterogeneity of our cohort. The
NB97 protocol clearly recommended less aggressive
surgical approach particularly during first operation in
an effort to avoid surgical complications. Most sur-
geons choose a less aggressive approach when the dis-
ease was considered to be unresectable during
operation. Thus, the question whether patients did
not undergo complete resection because of less ag-
gressive surgical approaches, or simply due to unre-
sectable disease cannot be answered retrospectively.
Moreover, less aggressive surgeons are more likely to
classify patients as unresectable and vice versa. Pro-
spective studies with a statement of the surgeon’s
decision in his/hers operation notes are needed to
address different approaches.
However, subgroup analyses showed better EFS and
OS for patients with complete resection in INSS stage 3
and MYCN amplification. Patients with MYCN amplifi-
cation belong to the INRG high-risk stratification and
are therefore of special interest since the role of surgery
in high-risk patients remains controversial. Other stud-
ies of high-risk patients especially evaluating stage 4
patients show no advantage of complete resection on
patient’s outcome [11, 16], while lower local recur-
rence rates and better OS are reported after extended
surgery by La Quaglia et al. [17, 18]. But analyzing
localized neuroblastoma in patients >1 year, radical
surgery is recommended which is in line with our
findings [2]. A meta-analysis of 2599 patients with
stage 3 and 4 neuroblastomas from 33 studies dem-
onstrated that relative risk of mortality was decreased
in patients who underwent >90% resection [19]. Our
study indicates that complete surgical resection of the
primary tumor site should be attempted in INRG
high-risk patients.
Risk of complications at first and best operation is
comparable to previously published data [2]. Since the
Table 2 Results of univariate outcome analysis of 179 patients with localized NB >18 months
Biopsy (<50%) Incomplete resection (50–90%) Gross total resection (90–95%) Complete resection (>95%) P (comparing
four groups)Survival Mean SD Mean SD Mean SD Mean SD
First operation
No. of Patients 69 13 14 83
5-year EFS 61.5 5.9 66.7 13.6 78.6 11.0 87.8 3.6 0.000
5-year OS 75.8 5.3 83.3 10.8 92.9 6.9 92.3 3.1 0.018
5-year LPFS 66.7 6.0 66.7 13.6 78.6 11.0 93.6 2.8 0.000
Best operation
No. of Patients 1 25 30 123
5-year EFS censored censored 58.0 10.2 59.8 9.0 82.8 3.4 0.001
5-year OS censored censored 70.5 9.4 75.4 8.1 90.8 2.7 0.020
5-year LPFS censored censored 66.2 10.4 62.7 9.0 87.1 3.1 0.001
Fig. 2 Kaplan-Meier-curves for all patients with localized NB (n = 179) after first operation
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presence of IDRF predicts the risk of complications and
the extent of surgery, the impact of IDRF should become
an integrated part of therapy planning as shown be-
fore [20–22], but cannot be safely used as an inde-
pendent risk factor for outcome. Therefore, INRG
classification considering IDRF, histological category,
MYCN amplification, grade of tumor differentiation
and chromosomal aberrations, was applied in our
study and showed a significant difference in high-risk
patients with complete surgical resection of the
tumor. Future trials should encourage a complete re-
section of the primary tumor in INRG high-risk pa-
tients with a more aggressive approach to improve
outcome with an acceptable risk of complication, but
probable life-threatening complications should still be
avoided.
In this study postoperative staging to assess the
presence and extent of possible residual tumors was
carried out by computed tomography, magnetic
resonance imaging or ultrasound, but MRI was rec-
ommended as gold standard for follow-up. The inter-
val between surgery and imaging varied between one
and three months postoperatively, which can result in
differences of the extent of resection described by
imaging studies and by operation notes. Whenever
there was inconsistency (26.7% of all cases), joint
review with a radiologist was performed.
Even in patients with localized neuroblastoma older
than 18 months, spontaneous regression or differen-
tiation can occur at any time throughout therapy.
This should be considered in patients with incom-
plete resection or gross total resection achieved at
first operation. In this study, only few patients with
incomplete/gross total resection after first operation
underwent second operations to achieve complete re-
section, whereas most patients did not (9 vs. 18).
Due to the small number of patients, a benefit of
further surgery in these cases remains unclear. Pos-
sibly, molecular characterization of the primary tu-
mors will be able to answer these questions in the
future.
Conclusion
In patients with localized neuroblastoma >18 months,
especially with INRG high-risk classification, extended
surgery improves EFS, LPFS and OS and should therefore
be attempted.
Fig. 4 Kaplan-Meier-curves for INRG high-risk patients after best operation
Fig. 3 Kaplan-Meier-curves for all patients with localized NB (n = 179) after best operation
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